产品中心

There was more gloom last week for British Biotech, the biotechnology company that fell from grace two years ago after it was censured by the London Stock Exchange for failing to inform investors of disappointing results in clinical trials. Last week, the company reported that Marimastat, its flagship product designed to halt the spread of primary cancers, had failed to help patients with advanced pancreatic cancer. The trial is only one of 10 involving Marimastat,